Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Core Insights - Adial Pharmaceuticals, Inc. has received a new patent (number 12150931) from the United States Patent and Trademark Office, enhancing its intellectual property portfolio [1][3] - The patent covers a wider range of genotype combinations for the treatment of alcohol use disorder (AUD) using the investigational drug AD04, which is part of the company's precision medicine approach [2][3] - The CEO of Adial Pharmaceuticals emphasized the importance of this patent in protecting AD04 and expanding its applications in personalized medicine, aiming for broad patent coverage until 2031 [3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting AUD [4] - AD04 is a genetically targeted serotonin-3 receptor antagonist that has shown promising results in reducing heavy drinking in patients during the ONWARD™ Phase 3 clinical trial [4] - The company believes AD04 may also have potential applications in treating other addictive disorders, including opioid use disorder, gambling, and obesity [4]